Selected publications of the first funding period at a glance
PIs of CRC1479 are first or last author and CRC1479 funding is indicated in the acknowledgement.
- Vinnakota JM et al. Nature Cancer 2024 doi: 10.1038/s43018-024-00764-7
- Schmitt M et al. Nature 2022 doi: 10.1038/s41586-022-05426-1
- Masuda T et al. Nature 2022 doi: 10.1038/s41586-022-04596-2
- Friedrich M et al. Nature Cancer 2022 doi: 10.1038/s43018-021-00201-z
- Sankowski R et al. Nature Medicine 2024 doi: 10.1038/s41591-023-02673-1
- Wertheimer T et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01755-7
- Maas-Bauer K et al. Nature Commun. 2024 doi: 10.1038/s41467-024-44703-7
- Velasco Cárdenas RM et al. Nature Immunol 2023 doi: 10.1038/s41590-023-01658
- Zhang YW et al. Nature Cell Biology 2022 doi: 10.1038/s41556-022-00931-x
- Ho J et al. Blood 2022 doi: 10.1182/blood.2022016082
- Rückert T et al. Sci Transl Med. 2022 doi: 10.1126/scitranslmed.abp9675.
- Talvard-Balland N et al. J Clin Invest. 2024 doi: 10.1172/JCI177460.
- Denk D et al. Immunity 2022 doi: 10.1016/j.immuni.2022.09.014
- Schmidt D et al. Cancer Res. 2024 doi: 10.1158/0008-5472.CAN-23-3553
- Nicolas AM et al. Cancer Cell. 2022 doi: 10.1016/j.ccell.2022.01.004
- Grünwald BT et al. Cell 2021 doi: 10.1016/j.cell.2021.09.022.
- Zhang Z et al. Nature Immunol. 2025 doi: 10.1038/s41590-024-02027-0.
- Braun L et al. Cancer Cell. 2025 doi: 10.1016/j.ccell.2025.01.004.
- Vinnakota JM et al. Sci Transl Med. 2024 doi: 10.1126/scitranslmed.adj9672.
- Edwards-Hicks J et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01419.
- Saller BS et al. Immunity 2024 doi: 10.1016/j.immuni.2024.10.012.
- Heim K et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01928-4.
- Gallage S et al. Cell Metab. 2024 doi: 10.1016/j.cmet.2024.04.015.
- Denk D et al. Immunity 2025 doi: 10.1016/j.immuni.2025.02.005
- Gorantla SP et al. Nature Commun 2025 doi: 10.1038/s41467-025-60019-6
Publications based on CRC1479 funding
Zeiser R. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2023 Feb 17:JCO2202256. doi: 10.1200/JCO.22.02256.
Amann L, Masuda T, Prinz M. Mechanisms of myeloid cell entry to the healthy and diseased central nervous system. Nat Immunol. 2023 Mar;24(3):393-407. doi: 10.1038/s41590-022-01415-8. Epub 2023 Feb 9.
Boonsanay V, Mosa MH, Looso M, Weichenhan D, Ceteci F, Pudelko L, Lechel A, Michel CS, Künne C, Farin HF, Plass C, Greten FR. Loss of SUV420H2-Dependent Chromatin Compaction Drives Right-Sided Colon Cancer Progression. Gastroenterology. 2023 Feb;164(2):214-227. doi: 10.1053/j.gastro.2022.10.036.
Conche C, Finkelmeier F, Pešić M, Nicolas AM, Böttger TW, Kennel KB, Denk D, Ceteci F, Mohs K, Engel E, Canli Ö, Dabiri Y, Peiffer KH, Zeuzem S, Salinas G, Longerich T, Yang H, Greten FR. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023 Jan 27:gutjnl-2022-327909. doi: 10.1136/gutjnl-2022-327909. Epub ahead of print.
Jaeger A, Gambheer SMM, Sun X, Chernyakov D, Skorobohatko O, Mack TM, Kissel S, Pfeifer D, Zeiser R, Fisch P, Andrieux G, Bräuer-Hartmann D, Bauer M, Schulze S, Follo M, Boerries M, von Bubnoff N, Miething C, Hidalgo JV, Klein C, Weber T, Wickenhauser C, Binder M, Dierks C. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023 Jan 25:blood.2022015653. doi: 10.1182/blood.2022015653.
Neuwirt E, Magnani G, Ćiković T, Wöhrle S, Fischer L, Kostina A, Flemming S, Fischenich NJ, Saller BS, Gorka O, Renner S, Agarinis C, Parker CN, Boettcher A, Farady CJ, Kesselring R, Berlin C, Backofen R, Rodriguez-Franco M, Kreutz C, Prinz M, Tholen M, Reinheckel T, Ott T, Groß CJ, Jost PJ, Groß O. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. Sci Signal. 2023 Jan 17;16(768):eabh1083. doi: 10.1126/scisignal. abh1083. Epub 2023 Jan 17.
